Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LPM6690176 plus chemotherapy and bevacizumab in RAS-mutant metastatic colorectal cancer
CTR20260099Phase 2Active
- Sponsor
- Yantai Chuanghe Biotechnology
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LY01024 in colorectal cancer (CRC), sponsored by Yantai Chuanghe Biotechnology. Started Feb 2026; status: active.
02
Drugs
LY01024
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20260099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260099.